Though third-generation EGFR inhibitor AZD9291 has achieved a great clinical benefit in NSCLC patients, the EGFRC797S acquired mutation would compromise the therapeutic efficacy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.